Artelo Biosciences, Inc. (ARTL)
NASDAQ: ARTL · Real-Time Price · USD
3.380
-0.030 (-0.88%)
Oct 8, 2026, 1:59 PM EDT - Market open
Artelo Biosciences Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 4.2 | 0.6 | 2.34 | 2.82 | 6.89 | 12.16 |
Short-Term Investments | - | - | - | - | 1.5 | - |
Trading Asset Securities | - | - | - | 7.61 | 9.15 | 11.95 |
Cash & Short-Term Investments | 4.2 | 0.6 | 2.34 | 10.43 | 17.53 | 24.11 |
Cash Growth | 103.19% | -74.34% | -77.58% | -40.53% | -27.29% | 139.57% |
Prepaid Expenses | 0.17 | 0.1 | 0.22 | 0.55 | 0.79 | 0.5 |
Total Current Assets | 4.37 | 0.7 | 2.56 | 10.98 | 18.32 | 24.61 |
Property, Plant & Equipment | 0.05 | 0.06 | 0.1 | 0.02 | 0.06 | 0.08 |
Long-Term Investments | - | - | - | - | - | 1.52 |
Other Intangible Assets | 2.04 | 2.04 | 2.04 | 2.04 | 2.04 | 2.04 |
Other Long-Term Assets | 0 | 0 | 0 | 0 | 0 | 0 |
Total Assets | 6.46 | 2.8 | 4.7 | 13.04 | 20.42 | 28.25 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 1.3 | 3.04 | 1.68 | 1.24 | 0.91 | 0.98 |
Accrued Expenses | 0.11 | 0.36 | 0.06 | 0.03 | 0.05 | 0.02 |
Short-Term Debt | - | 0.61 | - | - | - | - |
Current Portion of Leases | 0.04 | 0.04 | 0.04 | 0.02 | 0.04 | 0.03 |
Other Current Liabilities | - | 0 | - | - | - | - |
Total Current Liabilities | 1.46 | 4.04 | 1.77 | 1.29 | 1 | 1.03 |
Long-Term Leases | 0.01 | 0.03 | 0.07 | - | 0.02 | 0.06 |
Total Liabilities | 1.46 | 4.07 | 1.84 | 1.29 | 1.02 | 1.08 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0 | 0 | 0 | 0 | 0 | 0 |
Additional Paid-In Capital | 73.64 | 62.01 | 53.19 | 52.26 | 50.68 | 48.12 |
Retained Earnings | -68.4 | -63.02 | -50.14 | -40.31 | -31.02 | -20.94 |
Comprehensive Income & Other | -0.24 | -0.27 | -0.2 | -0.2 | -0.25 | -0.02 |
Shareholders' Equity | 5 | -1.27 | 2.86 | 11.75 | 19.4 | 27.17 |
Total Liabilities & Equity | 6.46 | 2.8 | 4.7 | 13.04 | 20.42 | 28.25 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 0.05 | 0.68 | 0.1 | 0.02 | 0.06 | 0.09 |
Net Cash (Debt) | 4.15 | -0.08 | 2.23 | 10.4 | 17.47 | 24.03 |
Net Cash Growth | 249.24% | - | -78.53% | -40.45% | -27.28% | 140.97% |
Net Cash Per Share | 33.53 | -2.05 | 112.32 | 569.34 | 998.97 | 1745.37 |
Filing Date Shares Outstanding | 0.51 | 0.08 | 0.02 | 0.02 | 0.02 | 0.02 |
Total Common Shares Outstanding | 0.47 | 0.07 | 0.02 | 0.02 | 0.02 | 0.02 |
Working Capital | 2.92 | -3.35 | 0.79 | 9.69 | 17.32 | 23.58 |
Book Value Per Share | 10.74 | -17.01 | 141.07 | 597.00 | 1100.69 | 1560.60 |
Tangible Book Value | 2.96 | -3.31 | 0.82 | 9.71 | 17.36 | 25.13 |
Tangible Book Value Per Share | 6.36 | -44.28 | 40.39 | 493.42 | 985.02 | 1443.47 |